440 related articles for article (PubMed ID: 24418325)
41. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
42. Inhibiting the immunoproteasome's β5i catalytic activity affects human peripheral blood-derived immune cell viability.
Pletinckx K; Vaßen S; Schlusche I; Nordhoff S; Bahrenberg G; Dunkern TR
Pharmacol Res Perspect; 2019 Aug; 7(4):e00482. PubMed ID: 31236277
[TBL] [Abstract][Full Text] [Related]
43. MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.
Jagannathan S; Vad N; Vallabhapurapu S; Vallabhapurapu S; Anderson KC; Driscoll JJ
Leukemia; 2015 Mar; 29(3):727-38. PubMed ID: 25234165
[TBL] [Abstract][Full Text] [Related]
44. Bortezomib-resistant mutant proteasomes: structural and biochemical evaluation with carfilzomib and ONX 0914.
Huber EM; Heinemeyer W; Groll M
Structure; 2015 Feb; 23(2):407-17. PubMed ID: 25599643
[TBL] [Abstract][Full Text] [Related]
45. Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.
Lü S; Chen Z; Yang J; Chen L; Gong S; Zhou H; Guo L; Wang J
Exp Hematol; 2008 Oct; 36(10):1278-84. PubMed ID: 18562081
[TBL] [Abstract][Full Text] [Related]
46. Interferon-γ induces immunoproteasomes and the presentation of MHC I-associated peptides on human salivary gland cells.
Arellano-Garcia ME; Misuno K; Tran SD; Hu S
PLoS One; 2014; 9(8):e102878. PubMed ID: 25102056
[TBL] [Abstract][Full Text] [Related]
47. ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5.
Yang Y; Gao Y; Huang J; Yang Z; Luo H; Wang F; Xu J; Cui Y; Ding H; Lin Z; Zhai X; Qu Y; Zhang L; Liu T; Ye L; Niu T; Zheng Y
JCI Insight; 2022 Oct; 7(19):. PubMed ID: 36040812
[TBL] [Abstract][Full Text] [Related]
48. Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance.
Wu YX; Yang JH; Saitsu H
Oncotarget; 2016 Nov; 7(47):77622-77634. PubMed ID: 27769058
[TBL] [Abstract][Full Text] [Related]
49. Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells.
Rückrich T; Kraus M; Gogel J; Beck A; Ovaa H; Verdoes M; Overkleeft HS; Kalbacher H; Driessen C
Leukemia; 2009 Jun; 23(6):1098-105. PubMed ID: 19225532
[TBL] [Abstract][Full Text] [Related]
50. Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.
Powers GL; Ellison-Zelski SJ; Casa AJ; Lee AV; Alarid ET
Oncogene; 2010 Mar; 29(10):1509-18. PubMed ID: 19946334
[TBL] [Abstract][Full Text] [Related]
51. Immunoproteasome Activity and Content Determine Hematopoietic Cell Sensitivity to ONX-0914 and to the Infection of Cells with Lentiviruses.
Vagapova E; Burov A; Spasskaya D; Lebedev T; Astakhova T; Spirin P; Prassolov V; Karpov V; Morozov A
Cells; 2021 May; 10(5):. PubMed ID: 34066177
[TBL] [Abstract][Full Text] [Related]
52. Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia.
Koyama D; Kikuchi J; Hiraoka N; Wada T; Kurosawa H; Chiba S; Furukawa Y
Leukemia; 2014 Jun; 28(6):1216-26. PubMed ID: 24301524
[TBL] [Abstract][Full Text] [Related]
53. Immunoproteasome subunit LMP2 expression is deregulated in Sjogren's syndrome but not in other autoimmune disorders.
Krause S; Kuckelkorn U; Dörner T; Burmester GR; Feist E; Kloetzel PM
Ann Rheum Dis; 2006 Aug; 65(8):1021-7. PubMed ID: 16414974
[TBL] [Abstract][Full Text] [Related]
54. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.
Chauhan D; Li G; Podar K; Hideshima T; Mitsiades C; Schlossman R; Munshi N; Richardson P; Cotter FE; Anderson KC
Blood; 2004 Oct; 104(8):2458-66. PubMed ID: 15217830
[TBL] [Abstract][Full Text] [Related]
55. Molecular mechanisms of bortezomib resistant adenocarcinoma cells.
Suzuki E; Demo S; Deu E; Keats J; Arastu-Kapur S; Bergsagel PL; Bennett MK; Kirk CJ
PLoS One; 2011; 6(12):e27996. PubMed ID: 22216088
[TBL] [Abstract][Full Text] [Related]
56. Identification of proteasome subunit beta type 6 (PSMB6) associated with deltamethrin resistance in mosquitoes by proteomic and bioassay analyses.
Sun L; Ye Y; Sun H; Yu J; Zhang L; Sun Y; Zhang D; Ma L; Shen B; Zhu C
PLoS One; 2013; 8(6):e65859. PubMed ID: 23762443
[TBL] [Abstract][Full Text] [Related]
57. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.
Sacco A; Aujay M; Morgan B; Azab AK; Maiso P; Liu Y; Zhang Y; Azab F; Ngo HT; Issa GC; Quang P; Roccaro AM; Ghobrial IM
Clin Cancer Res; 2011 Apr; 17(7):1753-64. PubMed ID: 21355079
[TBL] [Abstract][Full Text] [Related]
58. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C
Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661
[TBL] [Abstract][Full Text] [Related]
59. High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors.
Rushworth SA; Bowles KM; MacEwan DJ
Cancer Res; 2011 Mar; 71(5):1999-2009. PubMed ID: 21212410
[TBL] [Abstract][Full Text] [Related]
60. Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma.
Zhou Y; Liu X; Xue J; Liu L; Liang T; Li W; Yang X; Hou X; Fang H
J Med Chem; 2020 May; 63(9):4701-4715. PubMed ID: 32267687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
